sovaldi
$10 generic Solvaldi emerges in Bangladesh
March 10, 2015Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Pharma is boosting pipelines to avoid patent cliff
February 11, 2015Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …
Charity challenges Sovaldi patent
February 10, 2015Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization
Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …
Gilead expands UK presence with new London HQ
February 10, 2015Research and Development, Sales and Marketing Cambridge, Gilead, London, NICE, UK, johnson, medcity, sovaldi, uxbridge
Gilead is to create a new UK commercial secondary headquarters in central London doubling its UK workforce to 600 by …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
AbbVie Hep C combo pill ready for Europe
January 16, 2015Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi
The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
Pharma industry set for bumper 2015
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi
Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
Global drug spending set to top $1 trillion
November 20, 2014Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend
Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …
BMS claims advance with hepatitis C regimen
November 10, 2014Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi
Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …
Sovaldi misses estimates but still makes history
October 29, 2014Research and Development, Sales and Marketing FDA, Gilead, harvoni, hep C, sofosbuvir, sovaldi
The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …
Merck revenue falls
October 28, 2014Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi
Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …
